On Monday, August 10, Matinas BioPharma Hldgs MTNB will release its latest earnings report. Benzinga's outlook for Matinas BioPharma Hldgs is included in the following report.
Earnings and Revenue
Based on management's projections, Matinas BioPharma Hldgs analysts modeled for EPS of $-0.03 per share on sales of $20.00 thousand. In the same quarter last year, Matinas BioPharma Hldgs also reported EPS at $-0.03 on sales of $89.81 thousand. If the company were to match the consensus estimate when it reports Monday, earnings would not change. Here's how the company's reported EPS has compared to analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.03 | -0.03 | -0.03 | -0.03 |
| EPS Actual | -0.03 | -0.04 | -0.03 | -0.03 |
| Revenue Estimate | 30.00 K | 20.00 K | 10.00 K | 20.00 K |
| Revenue Actual | 0 | 0 | 0 | 89.81 K |
Stock Performance
Over the last 52-week period, shares of Matinas BioPharma Hldgs are up 32.91%.
Looking at these results, shareholders should be feeling unsatisfied with these results.
Don't be surprised to see the stock move on comments made during its conference call. Matinas BioPharma Hldgs is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://78449.themediaframe.com/dataconf/productusers/mtnb/mediaframe/37317/indexl.html
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
